stockrowRegeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.
- Revenue
- +36.3%
- EPS
- +36.0%
- Free cash flow
- +3.85%
- Total debt
- −26.6%
Quarter to September 2026, against a year earlier
Follow REGN
Alert me
Regeneron Pharmaceuticals, Inc. (REGN) Net income
Regeneron Pharmaceuticals, Inc.'s net income for fiscal 2025 was $4.5B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $4.8B. Over the past ten years it has ranged from $636.1M (fiscal 2015) to $8.1B (fiscal 2021); the current reading is higher than 91% of that period. Regeneron Pharmaceuticals, Inc. ranks 1st of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $4.5B | 2.09% |
| FY2024 | $4.4B | 11.61% |
| FY2023 | $4.0B | (8.87%) |
| FY2022 | $4.3B | (46.28%) |
| FY2021 | $8.1B | 129.86% |
| FY2020 | $3.5B | 66.05% |
| FY2019 | $2.1B | (13.44%) |
| FY2018 | $2.4B | 103.95% |
| FY2017 | $1.2B | 33.84% |
| FY2016 | $895.5M | 40.79% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $1.9B | 50.26% |
| Jun 2026 | $1.3B | 78.34% |
| Mar 2026 | $727.2M | (13.90%) |
| Dec 2025 | $844.6M | (42.15%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | $4.8B |
| VRTX Vertex Pharmaceuticals Incorporated compare | $4.0B |
| ARGX argenex SE compare | $1.6B |
| RPRX Royalty Pharma PLC compare | $1.3B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $915.6M |
| GMAB Genmab A/S Sponsored ADR compare | $906.0M |
| ROIV Roivant Sciences Ltd. compare | −$414.6M |
| RVMD Revolution Medicines, Inc. compare | −$1.9B |
| MRNA Moderna, Inc. compare | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on REGN
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement